Section of Paediatric Infectious Disease, Faculty of Medicine, and Centre for Paediatrics and Child Health, Imperial College London, London, UK.
Sanquin Research and Landsteiner Laboratory, Department of Immunopathology, Sanquin Blood Supply, Amsterdam University Medical Center (UMC), Amsterdam, Netherlands; Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Center (UMC), Amsterdam, Netherlands.
Lancet Digit Health. 2023 Nov;5(11):e774-e785. doi: 10.1016/S2589-7500(23)00149-8.
Differentiating between self-resolving viral infections and bacterial infections in children who are febrile is a common challenge, causing difficulties in identifying which individuals require antibiotics. Studying the host response to infection can provide useful insights and can lead to the identification of biomarkers of infection with diagnostic potential. This study aimed to identify host protein biomarkers for future development into an accurate, rapid point-of-care test that can distinguish between bacterial and viral infections, by recruiting children presenting to health-care settings with fever or a history of fever in the previous 72 h.
In this multi-cohort machine learning study, patient data were taken from EUCLIDS, the Swiss Pediatric Sepsis study, the GENDRES study, and the PERFORM study, which were all based in Europe. We generated three high-dimensional proteomic datasets (SomaScan and two via liquid chromatography tandem mass spectrometry, referred to as MS-A and MS-B) using targeted and untargeted platforms (SomaScan and liquid chromatography mass spectrometry). Protein biomarkers were then shortlisted using differential abundance analysis, feature selection using forward selection-partial least squares (FS-PLS; 100 iterations), along with a literature search. Identified proteins were tested with Luminex and ELISA and iterative FS-PLS was done again (25 iterations) on the Luminex results alone, and the Luminex and ELISA results together. A sparse protein signature for distinguishing between bacterial and viral infections was identified from the selected proteins. The performance of this signature was finally tested using Luminex assays and by calculating disease risk scores.
376 children provided serum or plasma samples for use in the discovery of protein biomarkers. 79 serum samples were collected for the generation of the SomaScan dataset, 147 plasma samples for the MS-A dataset, and 150 plasma samples for the MS-B dataset. Differential abundance analysis, and the first round of feature selection using FS-PLS identified 35 protein biomarker candidates, of which 13 had commercial ELISA or Luminex tests available. 16 proteins with ELISA or Luminex tests available were identified by literature review. Further evaluation via Luminex and ELISA and the second round of feature selection using FS-PLS revealed a six-protein signature: three of the included proteins are elevated in bacterial infections (SELE, NGAL, and IFN-γ), and three are elevated in viral infections (IL18, NCAM1, and LG3BP). Performance testing of the signature using Luminex assays revealed area under the receiver operating characteristic curve values between 89·4% and 93·6%.
This study has led to the identification of a protein signature that could be ultimately developed into a blood-based point-of-care diagnostic test for rapidly diagnosing bacterial and viral infections in febrile children. Such a test has the potential to greatly improve care of children who are febrile, ensuring that the correct individuals receive antibiotics.
European Union's Horizon 2020 research and innovation programme, the European Union's Seventh Framework Programme (EUCLIDS), Imperial Biomedical Research Centre of the National Institute for Health Research, the Wellcome Trust and Medical Research Foundation, Instituto de Salud Carlos III, Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Grupos de Refeencia Competitiva, Swiss State Secretariat for Education, Research and Innovation.
区分儿童发热时的自限性病毒感染和细菌感染是一个常见的挑战,这导致难以确定哪些患者需要使用抗生素。研究宿主对感染的反应可以提供有用的见解,并可能导致发现具有诊断潜力的感染生物标志物。本研究旨在通过招募因发热或发热史(72 小时内)而到医疗机构就诊的儿童,来确定宿主蛋白生物标志物,以便未来开发出一种能够准确、快速区分细菌和病毒感染的即时护理点检测方法。
在这项多队列机器学习研究中,患者数据来自欧洲的 EUCLIDS、瑞士儿科脓毒症研究、GENDRES 研究和 PERFORM 研究。我们使用靶向和非靶向平台(SomaScan 和液相色谱串联质谱法,分别称为 MS-A 和 MS-B)生成了三个高维蛋白质组数据集。使用差异丰度分析、基于正向选择-偏最小二乘法(FS-PLS;100 次迭代)的特征选择以及文献检索,对蛋白质生物标志物进行了筛选。使用 Luminex 和 ELISA 检测鉴定出的蛋白质,并再次对 Luminex 结果(单独进行)和 Luminex 和 ELISA 结果(联合进行)进行迭代 FS-PLS(25 次迭代)。从选定的蛋白质中确定了用于区分细菌和病毒感染的稀疏蛋白质特征。最后,通过使用 Luminex 检测和计算疾病风险评分来测试该特征的性能。
376 名儿童提供了血清或血浆样本,用于发现蛋白质生物标志物。为了生成 SomaScan 数据集,采集了 79 份血清样本;为了生成 MS-A 数据集,采集了 147 份血浆样本;为了生成 MS-B 数据集,采集了 150 份血浆样本。差异丰度分析和基于 FS-PLS 的第一轮特征选择确定了 35 个候选蛋白质生物标志物,其中 13 个有商业化的 ELISA 或 Luminex 检测方法。通过文献回顾,鉴定出了 16 个有 ELISA 或 Luminex 检测方法的蛋白质。通过 Luminex 和 ELISA 进一步评估,并进行基于 FS-PLS 的第二轮特征选择,发现了一个由 6 个蛋白质组成的特征:包括 3 个在细菌感染中升高的蛋白质(SELE、NGAL 和 IFN-γ)和 3 个在病毒感染中升高的蛋白质(IL18、NCAM1 和 LG3BP)。使用 Luminex 检测对该特征的性能进行测试,发现接受者操作特征曲线下面积在 89.4%至 93.6%之间。
本研究确定了一个蛋白质特征,最终可能会被开发成一种基于血液的即时护理点诊断测试,用于快速诊断发热儿童的细菌和病毒感染。这种测试有可能极大地改善发热儿童的护理,确保正确的患者使用抗生素。
欧盟地平线 2020 研究与创新计划、欧盟第七框架计划(EUCLIDS)、帝国理工学院生物医学研究中心国家卫生研究院、惠康信托基金会和医学研究基金会、西班牙卡洛斯三世卫生研究所、生物医学研究中心网络传染病研究竞争力参考小组、瑞士联邦教育、研究与创新署。